NDV01 enters Phase 3 with strong reported durability, substantial cash runway, and FDA alignment, but registration requires durable responses.
| Quarter | Q1 FY26 |
|---|---|
| Length | 34 minutes |
| EPS | $-0.22 |
| EPS consensus | $-0.18 |
| Revenue | $959762.00 |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25
All RLMD earnings · Back to RLMD overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.